Zura Bio (ZURA) Competitors $2.00 -0.02 (-0.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.08 +0.08 (+3.80%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZURA vs. OLMA, KOD, ATYR, AQST, ESPR, IVA, RAPP, CYRX, ZVRA, and PRMEShould you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), CryoPort (CYRX), Zevra Therapeutics (ZVRA), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Zura Bio vs. Its Competitors Olema Pharmaceuticals Kodiak Sciences aTyr Pharma Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Zevra Therapeutics Prime Medicine Olema Pharmaceuticals (NASDAQ:OLMA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends. Do institutionals and insiders believe in OLMA or ZURA? 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 16.4% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend OLMA or ZURA? Olema Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 208.88%. Zura Bio has a consensus price target of $14.00, indicating a potential upside of 600.00%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Zura Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer OLMA or ZURA? In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Zura Bio. MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.50 beat Olema Pharmaceuticals' score of 1.31 indicating that Zura Bio is being referred to more favorably in the news media. Company Overall Sentiment Olema Pharmaceuticals Positive Zura Bio Very Positive Is OLMA or ZURA more profitable? Olema Pharmaceuticals' return on equity of -42.58% beat Zura Bio's return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -42.58% -38.65% Zura Bio N/A -49.11%-40.06% Which has stronger valuation and earnings, OLMA or ZURA? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$129.47M-$1.98-3.92Zura BioN/AN/A-$45.39M-$0.70-2.86 Which has more volatility & risk, OLMA or ZURA? Olema Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. SummaryZura Bio beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Zura Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZURA vs. The Competition Export to ExcelMetricZura BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.34M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-2.8621.1774.5225.93Price / SalesN/A476.06548.33126.97Price / CashN/A46.6837.5660.44Price / Book0.889.6112.166.29Net Income-$45.39M-$53.29M$3.28B$270.77M7 Day Performance-9.09%0.28%0.87%3.88%1 Month Performance25.79%5.73%4.96%4.88%1 Year Performance-45.95%10.52%60.74%26.01% Zura Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZURAZura Bio3.6726 of 5 stars$2.00-1.0%$14.00+600.0%-44.4%$131.34MN/A-2.863Positive NewsShort Interest ↓OLMAOlema Pharmaceuticals2.8454 of 5 stars$7.58-8.8%$24.00+216.6%-34.4%$570.35MN/A-3.8370News CoveragePositive NewsAnalyst UpgradeKODKodiak Sciences3.858 of 5 stars$9.79-6.9%$11.75+20.0%+288.7%$555.68MN/A-2.5890ATYRaTyr Pharma2.5955 of 5 stars$5.46-2.7%$23.25+325.8%+222.5%$549.71M$230K-6.8253Positive NewsAQSTAquestive Therapeutics2.2446 of 5 stars$5.01-7.6%$10.29+105.3%+11.0%$540.50M$57.56M-7.16160Gap DownESPREsperion Therapeutics4.1054 of 5 stars$2.51-6.3%$7.00+178.9%+62.3%$540.35M$332.31M-5.12200Positive NewsIVAInventiva3.154 of 5 stars$5.37-3.6%$14.83+176.2%+149.3%$532.84M$9.95M0.00100Positive NewsShort Interest ↑Gap DownRAPPRapport Therapeutics2.6713 of 5 stars$31.47+119.2%$31.00-1.5%+25.6%$524.11MN/A-12.59N/ATrending NewsInsider TradeGap UpHigh Trading VolumeCYRXCryoPort3.7768 of 5 stars$10.04-3.0%$12.00+19.5%+4.3%$518.19M$228.38M7.551,186Positive NewsInsider TradeZVRAZevra Therapeutics2.7093 of 5 stars$8.33-6.9%$23.71+184.7%+2.1%$502.41M$23.61M-39.6720Positive NewsAnalyst DowngradePRMEPrime Medicine3.2813 of 5 stars$3.89+4.6%$8.92+129.2%+0.5%$500.62M$4.96M-1.90234 Related Companies and Tools Related Companies OLMA Alternatives KOD Alternatives ATYR Alternatives AQST Alternatives ESPR Alternatives IVA Alternatives RAPP Alternatives CYRX Alternatives ZVRA Alternatives PRME Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZURA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
